Background: Hypercholesterolemia. is an important risk factor for coronary
artery disease (CAD) and is associated with impaired endothelial function,
hypercoagulability, and increased platelet activation. The ability of stati
ns to reduce the mortality and morbidity associated with CAD may not be due
entirely to their lipid-lowering effects.
Objective: The aim of this study was to determine the effects of atorvastat
in on lipid profile and coagulation parameters.
Methods: Adults with documented hypercholesterolemia who did not respond to
dietary intervention alone and had not been treated pharmacologically were
enrolled. In accordance with the criteria of the American Heart Associatio
n guidelines, patients began therapy with atorvastatin 10 mg/d. Total chole
sterol (TC), low-density and high-density lipoprotein cholesterol (LDL-C an
d HDL-C), triglycerides (TG), fibrinogen, prothrombin time (PT), activated
partial thromboplastin time (aPTT), clot retraction time (CRT), and tissue
plasminogen activator (t-PA) levels were determined at baseline and at week
12 of treatment.
Results: A total of 8 men and 11 women (mean age, 57.2 +/- 10.0 years; rang
e, 43-77 years) were included in the study. Significant reductions from bas
eline in TC (baseline, 259.5 +/- 29.3 mg/dL; week 12, 186.2 +/- 39.9 mg/dL;
-28%) and LDL-C (baseline, 177.5 +/- 24.5 mg/dL; week 12,115.6 +/- 35.0 mg
/dL; -34%) were observed at the end of the study (P < 0.001). TG and HDL-C
levels did not change significantly (P > 0.05). CRT was shortened but remai
ned within the normal range (P < 0.05). t-PA levels decreased significantly
(baseline, 9.6 +/- 3.4 ng/mL; week 12, 6.5 +/- 3.5 ng/mL; P < 0.001), wher
eas PT, aPTT, and fibrinogen levels did not change significantly.
Conclusions: The data from this study suggest that treatment with atorvasta
tin decreases t-PA levels and CRT as well as lipid levels. The reduction in
t-PA and CRT may be a result of improvements in previously impaired endoth
elial function and coagulation.